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You are currently based in the School of 
Pharmacy at University College London 
(UCL). Can you provide an overview 
of the work you are undertaking?
I have over 25 years of experience studying 
the biological roles of inhibitory and excitatory 
neurotransmitter receptors, transporters and 
associated proteins in health and disease. 
My research has a strong translational 
aspect, aiming to convert basic science 
discoveries into clinical applications, such 
as improved genetic diagnostics, patient 
care and pharmacological treatments. I am 
also Associate Director for Research at the 
UCL School of Pharmacy, a role that involves 
research strategy and management. In addition, 
I contribute to several university committees 
at faculty level, including the Faculty of Life 
Sciences Senior Management Group and the 
UCL Open Access Academic Advisory Group.
How has your career led you to your 
current position?
After completing a PhD in Natural Sciences 
at the University of Cambridge, UK, I worked 
in Hamburg, Germany, for five years as 
a postdoctoral research assistant. I was 
fortunate enough to be awarded a Max-Planck 
fellowship in Frankfurt with Heinrich Betz, who 
stimulated my interest in glycine receptors 
and transporters. I have run my own research 
group at the School of Pharmacy at UCL since 
1998, and was promoted to Professor in 2007.
What is the motivation for your research 
into hyperekplexia, more commonly 
known as startle disease?
It is a rare neurological disease that affects 
humans as well as several animal species, 
including dogs, horses and cattle. The 
identification and functional characterisation of 
mutations in genes involved in this disease have 
improved both genetic diagnostics and patient 
care – a strong motivation to continue forging 
a fuller understanding of startle disease.
Can you discuss your role as professor? What 
do you enjoy most about teaching students 
at the beginning of their scientific careers?
Today, professors have so many different roles 
that it is easy to lose count. For example, 
in addition to my existing responsibilities, I 
recently learnt aspects of website design in 
order to redevelop the UCL School of Pharmacy 
website. As for teaching, it is an activity I 
particularly enjoy – and I currently lecture 
first-year students on genetics, second-year 
students on cardiovascular diseases and 
final-year students on substance abuse. I am 
very proud of our students who are completing 
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KNOWN AS STARTLE DISEASE, 
hyperekplexia is an inherited condition that 
affects newborn babies. Characterised 
by exaggerated responses triggered by 
unexpected sound, touch or visual stimuli, 
this disorder causes the chest and throat 
muscles of infants to freeze, their limbs to go 
rigid and – in some cases – their breathing 
to stop. Startle disease is also associated 
with swallowing and weaning difficulties and 
is a potential cause of sudden infant death.
This disease is extremely distressing for 
parents of the affected infant. Fortunately, 
however, treatments are available. The 
benzodiazepine Clonazepam is one of the 
most commonly used drugs, while the 
life-saving Vigevano manoeuvre – which 
involves the forced flexion of the head and 
limbs towards the trunk of the body – can 
help combat the effects of acute muscle 
stiffness and apnoea. Although the clinical 
symptoms of this condition tend to gradually 
diminish throughout the first year of life, 
in some cases the pronounced startle 
response and muscle stiffness can continue 
into adulthood, putting sufferers at risk of 
serious injuries and loss of ambulation as 
a result of sudden and unprotected falls.
MAKING INSIGHTS
Hyperekplexia was first recognised in 1962, 
when it was described in a paper entitled 
‘An unidentified hereditary disease’ in The 
Lancet by two Dutch researchers, Drs O 
Kok and G W Bruyn. Although its exact 
incidence remains unknown today, startle 
disease is extremely rare and has been 
estimated to affect approximately 1,000 
people worldwide. Disorders that resemble 
hyperekplexia have also been identified in 
animals, including mice, dogs, cattle and 
horses – often at a much higher prevalence 
than in humans, and with fatal consequences.
a Master’s degree in Pharmacy as they are 
highly professional and have a great attitude for 
learning. I also find that hosting students for 
final-year research projects is very rewarding – 
especially seeing them learn research methods, 
become experts on a topic and develop the 
necessary skills they need to become lifelong 
learners in such a short space of time.
How does collaborative research 
benefit your work? 
Collaboration is essential in my field as 
projects often operate across different 
disciplines; for example, they encompass 
aspects of genetics, biochemistry, molecular 
biology and electrophysiology. With modern 
communications, collaborative projects can 
operate over international boundaries; we 
have many partners in Europe and further 
afield in countries such as Japan and the 
US. By pooling our resources and expertise, 
these joint initiatives often make significant 
contributions to the scientific knowledge base 
and result in publications in high-impact 
journals. However, they are also a great 
way to learn new scientific techniques.
Moreover, collaborators often become lifelong 
friends and provide one another with interesting 
opportunities and experiences. For example, 
I was recently fortunate enough to spend a 
week in Japan with a long-term collaborator, 
Hiromi Hirata, who was kind enough to take 
me to a restaurant serving Fugu – a fish 
which can be fatal if prepared incorrectly!
Where do you see your career 
taking you in 10 years’ time?
I hope that I will still be running a successful, 
funded research programme that addresses 
fundamental questions in health and disease. 
A senior leadership role in an academic 
setting is also a strong possibility; I would 
be very open to the prospect of running a 
thriving research department that works in 
the area of translational neuroscience.
 Startle disease and faulty genes
In an attempt to enhance genetic diagnostics and patient care, researchers based in the School 
of Pharmacy at University College London are investigating the biological roles of inhibitory and 
excitatory neurotransmitter receptors, transporters and proteins in neurological diseases
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One prominent researcher whose work has 
fundamentally advanced understanding of 
the underlying genetic causes of startle 
disease is Robert Harvey, Professor of 
Molecular Neuroscience and Genetics and 
Associate Director for Research at the School 
of Pharmacy at University College London 
(UCL). In recent years, he has conducted 
numerous game-changing studies that 
have mined the complex mechanisms that 
underpin these diseases in both humans and 
animals. With an overarching emphasis on 
clinical translation, Harvey and his colleagues 
are committed to converting their scientific 
discoveries into practical applications that 
include improved genetic diagnostics, patient 
care and pharmacological treatments.
INVESTIGATING GENETICS
The gene mutations that cause startle disease 
trigger communication and cell signalling 
defects in the spinal cord and brainstem, in 
turn causing exaggerated startle reactions, 
abnormal muscle movements and other 
characteristic symptoms. A number of different 
genes are associated with the disease – most 
of which play a role in producing proteins found 
in neurons and governing how they respond 
to the neurotransmitter glycine. The majority 
of cases are known to be caused by mutations 
in the gene GLRA1, which encodes the glycine 
receptor α1 subunit. Mutations in GLRA1 lead 
to the production of a flawed receptor that is 
unable to respond properly to glycine. More 
recently, Harvey and Professor Mark Rees at 
the University of Swansea, UK, have identified 
numerous startle disease mutations in GLRB, 
encoding the glycine receptor beta subunit.
However, by drawing on a range of cutting-
edge technologies and techniques – including 
polymerase chain reaction, DNA sequencing, 
and cellular and computational models 
of receptor and transporter function and 
dysfunction – Harvey and Rees highlighted 
a major role for another gene in startle 
disease: SLC6A5. Their studies have provided 
conclusive evidence that missense, nonsense 
and frameshift mutations in SLC6A5 – the 
gene responsible for encoding the presynaptic 
glycine transporter known as GlyT2 – result in 
symptoms such as hypertonia, a pronounced 
startle response to tactile or acoustic stimuli 
and life-threatening apnoea episodes in 
early infancy. In contrast to individuals with 
hyperekplexia caused by GLRA1 mutations, 
individuals with SLC6A5 mutations show 
high rates of neonatal apnoea episodes, 
developmental delay and difficulties with 
speech acquisition, demonstrating that 
there is variation between the symptoms 
depending on the affected gene.
Importantly, this innovative research not only 
proves that SLC6A5 is a key gene involved in 
startle disease, but also uncovers the first 
human neurological disorder connected to 
alterations in a Na+/Cl–-dependent transporter 
for a classical fast neurotransmitter. The 
implications of these findings are significant, 
as they imply that in other human diseases 
linked to defects in postsynaptic receptors, 
similar symptoms could be induced as a 
result of defects in the cognate presynaptic 
neurotransmitter transporter. Additionally, the 
results highlight the necessity of including 
both presynaptic and postsynaptic causes 
of startle disease in genetic screening tests 
for the disease. Improved genetic diagnoses 
mean that babies with the disease can 
be monitored and properly treated, thus 
dramatically improving quality of life.
DRIVING CLINICAL BENEFITS
Ultimately, by unveiling their crucial roles in 
health and disease, Harvey’s research has 
transformed understanding of the postsynaptic 
inhibitory glycine receptors and the cognate 
presynaptic glycine transporter. Indeed, 
his findings have linked both dysfunctional 
inhibitory transmission of glycine and defects 
in receptor-associated clustering molecules 
associated to a range of serious disorders 
such as autism, anxiety, epilepsy, inflammatory 
pain, intellectual disability and rhythmic 
breathing. Going forwards, these receptors 
and transmitters could prove to be excellent 
therapeutic targets for those disorders.
Recent studies conducted by Harvey and his 
colleagues have highlighted that genetic defects 
in genes for NMDA receptor subunits – namely, 
GluN2A and GluN2B – cause various forms of 
childhood epilepsy, intellectual disability, autism 
and schizophrenia. The initial results imply 
that many of the genetic changes identified 
in these children lead to the over-excitation 
of neurons via gain-of-function mutations 
With an overarching emphasis on clinical translation, Harvey and his colleagues are committed 
to converting their scientific discoveries into practical applications that include improved genetic 
diagnostics, patient care and pharmacological treatments
FOCUS ON FUNDING
Harvey has had enormous success in securing funding for his research. In 2012, for instance, he received two prestigious awards totalling 
£500,000. More recently his team has obtained a grant worth £794,896 from the Medical Research Council to investigate the role of 
excitatory NMDA receptors in neurological disease. 
At a time when competition for research funding is increasingly fraught and intense, he shares some guidance for achieving 
success in this area: “My advice to junior investigators is to take plenty of time and write a well-structured, compelling application 
that addresses a fundamental set of questions,” he states. “Having your grant application read and critiqued by experienced 
scientists is essential – and studying examples of previously successful funding applications can also be very informative.”
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ROBERT HARVEY obtained his PhD 
in Natural Sciences (Biochemistry) 
from the University of Cambridge, 
UK, in 1991. Following postdoctoral 
studies at the Institute for Cell Biology 
and Clinical Neurobiology, Hamburg, Germany (1991-
96) and the Max-Planck-Institute for Brain Research, 
Frankfurt, Germany (1996-98), he moved to the UCL’s 
School of Pharmacy as Lecturer in 1998. He is now 
Professor of Molecular Neuroscience and Genetics and 
Associate Director for Research. His main area of interest 
is neurotransmission mediated by glycine, GABA and 
glutamate. His research also has a strong translational 
aspect – he aims to convert basic science discoveries 
into clinical applications, such as improved genetic 
diagnostics, patient care and pharmacological treatments.
INTELLIGENCE
REAL-WORLD IMPACT
Harvey is passionate about conducting basic research with real-
world impact. For instance, the discovery that mutations in the 
GlyT2 gene can lead to startle disease associated with breathing 
difficulties has meant that parents of affected infants can be 
provided with specialist heart rate and breathing monitors and 
given training in life-saving resuscitation techniques. 
Dedicated to maximising the impact of his research, Harvey is also 
devoted to engaging with the public and delivering both national and 
international lectures about his illuminating discoveries. He has had 
many speaking engagements in Europe, North America and Australia.
PROMOTING ANIMAL WELFARE
Harvey and his colleagues have devoted several studies to examining 
the causes of genetic defects of startle disease in dogs and cattle. 
Their findings have had important implications for promoting animal 
welfare and increasing economic return for farmers. For example:
• The use of artificial insemination through elite sires in cattle 
breeding has increased the frequency of recessive genetic disorders 
in livestock. In response, Harvey and his collaborators have 
demonstrated that the use of genome-wide, high-density single 
nucleotide polymorphism panels, together with the typical structure 
of livestock populations, increases the positional identification of 
defect-causing genes and mutations. This enables at-risk mating 
to be avoided as a result of marker-assisted selection against the 
defects and as such has had a positive impact on breeding practices
• Tests conducted on Belgian Blue calves on a UK farm, along with a 
sample of Belgian Blue sires, led Harvey and his team to develop a 
series of cost-effective tests for the congenital muscular dystonia 
type 2 allele. These tests can be used to confirm a diagnosis, 
identify carriers and inform breeding strategy in the future
• Further studies have found that startle disease in Irish Wolfhounds is 
linked to a microdeletion in the SLC6A5 gene – and have also pinpointed 
a total of 13 carriers of this deletion in related animals. Harvey and 
his collaborators aim to use these results to guide future breeding 
strategies and lead to the development of viable therapeutics
in NMDA receptor genes. As a result, 
the researchers are currently planning 
to explore the potential of glycine 
transporters as therapeutic targets. 
Indeed, inhibiting the glycine transporter 
GlyT1 increases the activity of excitatory 
NMDA-type glutamate receptors, which 
play a key role in learning and memory 
processes. “Inhibiting GlyT1 could be a 
potential remedy against the cognitive 
and affective deficiencies we observe 
in schizophrenic patients,” Harvey 
elucidates. “Additionally, because GlyT1 
can suppress alcohol intake in rodents, 
it may also be of use in the treatment 
of alcohol dependency in humans.”
Looking to the future, Harvey hopes his 
research at UCL will continue to bring 
tangible clinical benefits to the lives of 
those who are affected by startle disease 
and related diseases, such as childhood 
epilepsies. However, therapeutic 
advances are dependent on increasing 
knowledge about the complex molecular 
and physiological effects of glycine 
reuptake inhibition. In view of this, Harvey 
and his team are aiming to continue 
forging innovative insights into new 
possibilities for the control of glycinergic 
transmission in an attempt to realise the 
full potential of glycine receptors and 
transporters as therapeutic targets.
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